Nanomaterials Application as Drug Delivery Systems to the Treatment of Neurodegenerative Diseases
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: closed (25 November 2023) | Viewed by 1120
Special Issue Editors
Interests: nanomaterials synthesis; inorganic nanomaterials; organic nanomaterials; nanomaterials characterization; drug delivery; neurodegenerative diseases; brain tumors
Interests: neurodegeneration; Alzheimer disease; epilepsy; Parkinson; tau protein; amyloid b
Special Issue Information
Dear Colleagues,
Nowadays, the survival time of people has increased considerably, but unfortunately, their quality of life is not desirable. The long survival time allows us to observe the development of degenerative diseases such as neurodegenerative diseases. These later are characterized by the progressive loss of the structure or function of neurons, which often leads to neuronal death, affecting functions related to movement, memory, and dementia, among others. Its treatment is complicated because the drugs cause severe side effects since many cross the blood-brain barrier in small quantities, leading to increased doses to reach the adequate therapeutic amount. Therefore, using inorganic and organic nanomaterials and their combination as controlled drug delivery systems is an alternative because most are biocompatible with the human body. In addition, they can be functionalized to be directed to specific targets and cross the blood-brain barrier. Therefore, it is interesting to know the current nanomaterials' state of the art in applying neurological drug delivery systems to treat various neurodegenerative diseases.
Dr. Emma Ortiz-Islas
Dr. Victoria Campos-Peña
Dr. Citlali Ekaterina Rodríguez Pérez
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanomaterials
- drug delivery
- neurodegenerative diseases
- blood-brain barrier
- functionalization
- neuronal death
- biocompatible
